JMP Group LLC announced that Fedora Baloiu has joined JMP Securities as a managing director and co-head of biopharma corporate finance. Additionally, Silvan Tuerkcan and Gobind Singh, a director and vice president, respectively, have both joined JMP Securities as senior equity research analysts focused on the biotechnology sector. All three are based in the firm’s New York office. In connection with these key additions to JMP Securities’ life sciences franchise, David Kellman, a managing director and head of healthcare investment banking, will also serve as co-head of biopharma corporate finance, while David Schechner, a managing director in the healthcare investment banking group, has been named head of biopharma mergers and acquisitions. Prior to joining JMP Securities, Ms. Baloiu was a managing director and head of U.S. healthcare investment banking at Nomura Securities. She previously served as head of the biopharmaceuticals practice at Houlihan Lokey, after spending nearly a decade in the healthcare investment banking division at Goldman Sachs & Co.Ms. Prior to joining JMP Securities, Mr. Tuerkcan was an executive director and senior research analyst covering biotechnology at both UBS and Oppenheimer & Co. He previously worked in equity research at Goldman Sachs & Co.